ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "E111: PEXIVAS Subsets with Mike Walsh & Mats Junek"
Episode Synopsis
At ACR23 I had a twitter-disagreement about steroid tapers from PEXIVAS with Mike Walsh, the lead author on the PEXIVAS trial. He kindly agreed to join me for a moderated discussion. Loved hearing his perspective and have to admit he pulled me closer to his practice... but not all the way there. Longer podcast than usual but I prefer to release audio uncut and this took as long as it needed! Hoping y'all enjoy.
Articles referenced during the podcast:
PEXIVAS: https://www.nejm.org/doi/full/10.1056/nejmoa1803537
PEXIVAS DAH Subset: https://www.atsjournals.org/doi/10.1164/rccm.202308-1426OC
Fussner Abstract: https://acrabstracts.org/abstract/characteristics-and-outcomes-of-participants-with-and-without-diffuse-alveolar-hemorrhage-in-the-plasma-exchange-and-glucocorticoids-in-severe-anca-associated-vasculitis-pexivas-trial/
Walsh Meta Analysis: https://pubmed.ncbi.nlm.nih.gov/35217545/
Articles referenced during the podcast:
PEXIVAS: https://www.nejm.org/doi/full/10.1056/nejmoa1803537
PEXIVAS DAH Subset: https://www.atsjournals.org/doi/10.1164/rccm.202308-1426OC
Fussner Abstract: https://acrabstracts.org/abstract/characteristics-and-outcomes-of-participants-with-and-without-diffuse-alveolar-hemorrhage-in-the-plasma-exchange-and-glucocorticoids-in-severe-anca-associated-vasculitis-pexivas-trial/
Walsh Meta Analysis: https://pubmed.ncbi.nlm.nih.gov/35217545/
More episodes of the podcast The Evidence Based Rheumatology Podcast
E127: TNFs and All That CHF
22/09/2025
E126: Risk Signals, JAKs, and SELECTIVE-ity
08/09/2025
E122: Guidelines for Maybe Diagnosing HLH
17/04/2025
E121: Obinutuzumab in SLE-LN
02/04/2025
E120: Real Life Use of PEXIVAS-Low
06/03/2025
In God we trust